Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas.  (ASCO 2011, Plenary Session, Abstract LBA4)

P. B. Chapman; A. Hauschild; C. Robert; J. M. G. Larkin; J. B. A. G. Haanen; A. Ribas; D. Hogg; S. O'Day; P. A. Ascierto; A. Testori; P. Lorigan; R. Dummer; J. A. Sosman; C. Garbe; R. J. Lee; K. B. Nolop; B. Nelson; J. Hou; K. T. Flaherty; G. A. McArthur

doi:10.1200/jco.2011.29.15_suppl.lba4

Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. (ASCO 2011, Plenary Session, Abstract LBA4)

P. B. Chapman, A. Hauschild, C. Robert, J. M. G. Larkin, J. B. A. G. Haanen, A. Ribas, D. Hogg, S. O'Day, P. A. Ascierto, A. Testori, P. Lorigan, R. Dummer, J. A. Sosman, C. Garbe, R. J. Lee, K. B. Nolop, B. Nelson, J. Hou, K. T. Flaherty, G. A. McArthur

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	LBA4-LBA4
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	29
Issue number	Supplement 15
DOIs	https://doi.org/10.1200/jco.2011.29.15_suppl.lba4
Publication status	Published - 20 May 2011

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/jco.2011.29.15_suppl.lba4

Cite this

Chapman, P. B., Hauschild, A., Robert, C., Larkin, J. M. G., Haanen, J. B. A. G., Ribas, A., Hogg, D., O'Day, S., Ascierto, P. A., Testori, A., Lorigan, P., Dummer, R., Sosman, J. A., Garbe, C., Lee, R. J., Nolop, K. B., Nelson, B., Hou, J., Flaherty, K. T., & McArthur, G. A. (2011). Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. (ASCO 2011, Plenary Session, Abstract LBA4). Journal of Clinical Oncology, 29(Supplement 15), LBA4-LBA4. https://doi.org/10.1200/jco.2011.29.15_suppl.lba4

@article{29101e47775448ffb52da1768de63db6,

title = "Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. (ASCO 2011, Plenary Session, Abstract LBA4)",

author = "Chapman, {P. B.} and A. Hauschild and C. Robert and Larkin, {J. M. G.} and Haanen, {J. B. A. G.} and A. Ribas and D. Hogg and S. O'Day and Ascierto, {P. A.} and A. Testori and P. Lorigan and R. Dummer and Sosman, {J. A.} and C. Garbe and Lee, {R. J.} and Nolop, {K. B.} and B. Nelson and J. Hou and Flaherty, {K. T.} and McArthur, {G. A.}",

note = "JCO (2011)29(15_suppl) LBA4-LBA4 DOI: 10.1200/jco.2011.29.15_suppl.lba4 ",

year = "2011",

month = may,

day = "20",

doi = "10.1200/jco.2011.29.15_suppl.lba4",

language = "English",

volume = "29",

pages = "LBA4--LBA4",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins",

number = "Supplement 15",

}

Chapman, PB, Hauschild, A, Robert, C, Larkin, JMG, Haanen, JBAG, Ribas, A, Hogg, D, O'Day, S, Ascierto, PA, Testori, A, Lorigan, P, Dummer, R, Sosman, JA, Garbe, C, Lee, RJ, Nolop, KB, Nelson, B, Hou, J, Flaherty, KT & McArthur, GA 2011, 'Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. (ASCO 2011, Plenary Session, Abstract LBA4)', Journal of Clinical Oncology, vol. 29, no. Supplement 15, pp. LBA4-LBA4. https://doi.org/10.1200/jco.2011.29.15_suppl.lba4

Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. (ASCO 2011, Plenary Session, Abstract LBA4). / Chapman, P. B.; Hauschild, A.; Robert, C. et al.
In: Journal of Clinical Oncology, Vol. 29, No. Supplement 15, 20.05.2011, p. LBA4-LBA4.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. (ASCO 2011, Plenary Session, Abstract LBA4)

AU - Chapman, P. B.

AU - Hauschild, A.

AU - Robert, C.

AU - Larkin, J. M. G.

AU - Haanen, J. B. A. G.

AU - Ribas, A.

AU - Hogg, D.

AU - O'Day, S.

AU - Ascierto, P. A.

AU - Testori, A.

AU - Lorigan, P.

AU - Dummer, R.

AU - Sosman, J. A.

AU - Garbe, C.

AU - Lee, R. J.

AU - Nolop, K. B.

AU - Nelson, B.

AU - Hou, J.

AU - Flaherty, K. T.

AU - McArthur, G. A.

N1 - JCO (2011)29(15_suppl) LBA4-LBA4 DOI: 10.1200/jco.2011.29.15_suppl.lba4

PY - 2011/5/20

Y1 - 2011/5/20

UR - http://www.mendeley.com/research/phase-iii-randomized-openlabel-multicenter-trial-brim3-comparing-braf-inhibitor-rg7204-dacarbazine-p

U2 - 10.1200/jco.2011.29.15_suppl.lba4

DO - 10.1200/jco.2011.29.15_suppl.lba4

M3 - Article

SN - 0732-183X

VL - 29

SP - LBA4-LBA4

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - Supplement 15

ER -

Chapman PB, Hauschild A, Robert C, Larkin JMG, Haanen JBAG, Ribas A et al. Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. (ASCO 2011, Plenary Session, Abstract LBA4). Journal of Clinical Oncology. 2011 May 20;29(Supplement 15):LBA4-LBA4. doi: 10.1200/jco.2011.29.15_suppl.lba4

Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. (ASCO 2011, Plenary Session, Abstract LBA4)

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Other files and links

Cite this